Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acrivon Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/11/2023 8-K Quarterly results
Docs: "Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights WATERTOWN, Massachusetts, August 11, 2023 - Acrivon Therapeutics, Inc. , a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today reported financial results for the second quarter ended June 30, 2023 and provided business highlights. “The Acrivon team has made significant progress during the second quarter, both on the clinical and preclinical development fronts, as well as with the expansion of our board and executive leadership team with strategic additions,” said Peter Blume-Jensen, ..."
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
06/12/2023 144 Form 144 - Report of proposed sale of securities:
06/05/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Amended and Restated Employment Agreement, by and between Acrivon Therapeutics, Inc. and Kristina M. Masson",
"Contract of Employment, by and between Acrivon AB and Kristina M. Masson"
05/30/2023 DEFR14A Form DEFR14A - Revised definitive proxy soliciting materials:
05/09/2023 8-K Quarterly results
Docs: "Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights WATERTOWN, Massachusetts, May 9, 2023 - Acrivon Therapeutics, Inc. , a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today reported financial results for the first quarter ended March 31, 2023 and reviewed business highlights. “We are breaking the mold for precision oncology drug development and believe that Acrivon's predictive precision proteomics platform has paradigm-changing potential for improving patient treatment outcomes and the probability of clinical success,” said Peter Bl..."
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/01/2023 ARS Form ARS - Annual Report to Security Holders:
05/01/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/01/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/01/2023 8-K Investor presentation
Docs: "Acrivon Therapeutics, Inc. Presentation"
05/01/2023 8-K Quarterly results
04/25/2023 8-K Quarterly results
03/29/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/28/2023 10-K Annual Report for the period ended December 31, 2022
03/28/2023 8-K Quarterly results
03/13/2023 8-K Investor presentation
Docs: "Acrivon Therapeutics, Inc. Presentation",
"Acrivon Therapeutics, Inc. Presentation"
02/14/2023 SC 13G/A Sands Capital Ventures, LLC reports a 7.9% stake in Acrivon Therapeutics, Inc.
02/14/2023 SC 13G/A PERCEPTIVE ADVISORS LLC reports a 14.4% stake in Acrivon Therapeutics, Inc.
02/14/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
12/15/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/28/2022 SC 13D RA CAPITAL MANAGEMENT, L.P. reports a 23.1% stake in ACRIVON THERAPEUTICS, INC.
11/28/2022 SC 13G Chione Ltd reports a 18.5% stake in Acrivon Therapeutics, Inc.
11/25/2022 SC 13G Sands Capital Life Sciences Pulse Fund II, L.P. reports a 7.9% stake in Acrivon Therapeutics, Inc.
11/21/2022 SC 13G CITADEL ADVISORS LLC reports a 7.8% stake in Acrivon Therapeutics, Inc.
11/18/2022 SC 13G PERCEPTIVE ADVISORS LLC reports a 14.4% stake in Acrivon Therapeutics, Inc.
11/17/2022 8-K Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Even...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 14, 2022 Acrivon Therapeutics, Inc. Delaware 001-41551 82-5125532 480 Arsenal Way, Suite 100 Watertown, Massachusetts 02472 207-8979 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuan...",
"Amended and Restated Certificate of Incorporation of the Registrant",
"Amended and Restated Bylaws of the Registrant",
"Share Purchase Agreement, by and between the Company and Chione Limited"
11/17/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
11/16/2022 424B4 Form 424B4 - Prospectus [Rule 424(b)(4)]:
11/14/2022 S-1MEF Form S-1MEF - Registration adding securities to prior Form S-1 registration [Rule 462(b)]:
11/14/2022 FWP Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses:
11/08/2022 CERT Form CERT - Certification by an exchange approving securities for listing:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy